FEDERAL COURT OF AUSTRALIA
Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd [2013] FCA 226
Citation: Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd [2013] FCA 226 Parties: BAYER PHARMA AKTIENGESELLSCHAFT and BAYER AUSTRALIA LIMITED ACN 000 138 714 v GENERIC HEALTH PTY LTD ACN 110 617 859 and LUPIN AUSTRALIA PTY LTD ACN 112 038 105 File number(s): NSD 236 of 2012 Judge: JAGOT J Date of judgment: 11 March 2013 Catchwords: EVIDENCE – experimental proof of a fact – manufacture of tablets for subsequent tests – party denied opportunity to observe – application for leave – leave refused Legislation: Evidence Act1995 (Cth)
Federal Court Rules 2011Cases cited: Lexmark International v Boomerang Imaging Supplies Pty Ltd (2001) 112 FCR 331; [2001] FCA 833
Mölnlycke Health Care AB v Brightwake Limited (2011) FSR 26; [2011] EWHC 140Date of hearing: 11 March 2013 Place: Sydney Division: GENERAL DIVISION Category: Catchwords Number of paragraphs: 29 Counsel for the First and Second Applicants: D Shavin QC with Helen Rofe Counsel for the First and Second Respondents: A H Bowne SC with A D B Fox Solicitor for the First and Second Applicants: Davies Collison Cave Law Solicitor for the First and Second Respondents: K & L Gates
THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
GENERAL DIVISION
NSD 236 of 2012
BETWEEN: BAYER PHARMA AKTIENGESELLSCHAFT
First ApplicantBAYER AUSTRALIA LIMITED ACN 000 138 714
Second ApplicantAND: GENERIC HEALTH PTY LTD ACN 110 617 859
First RespondentLUPIN AUSTRALIA PTY LTD ACN 112 038 105
Second Respondent
JUDGE:
JAGOT J
DATE OF ORDER:
11 MARCH 2013
WHERE MADE:
SYDNEY
THE COURT ORDERS THAT:
1.The interlocutory application filed 5 March 2013 be dismissed.
2.The respondents are to pay the applicants’ costs of the interlocutory application as agreed or taxed.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
GENERAL DIVISION
NSD 236 of 2012
BETWEEN: BAYER PHARMA AKTIENGESELLSCHAFT
First ApplicantBAYER AUSTRALIA LIMITED ACN 000 138 714
Second ApplicantAND: GENERIC HEALTH PTY LTD ACN 110 617 859
First RespondentLUPIN AUSTRALIA PTY LTD ACN 112 038 105
Second Respondent
JUDGE:
JAGOT J
DATE:
11 MARCH 2013
PLACE:
SYDNEY
REASONS FOR JUDGMENT
This is an interlocutory application filed 5 March 2013 and returnable for hearing this morning, the first day of the hearing of this matter. The respondents seek leave to rely upon the affidavit of Terence Clive Burgess sworn 27 September 2012 filed in the proceedings as part of the respondents’ evidence in chief on validity. The interlocutory application was filed in response to the applicants giving the respondents notice that there would be objection taken to Mr Burgess’s affidavit.
The first issue for determination is whether r 34.50 of the Federal Court Rules 2011 is engaged. That rule provides that if a party proposes to tender as evidence in a proceeding experimental proof of a fact, the proponent…
Keep reading for free
Create a free CaseChat account to read Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2013] FCA 226
- Decision Date
CaseChat Overview and Summary
The primary legal issue before the Court was whether Bayer should be granted leave to observe the manufacturing process at Generic Health's facility. Bayer argued that such inspection was necessary to gather experimental evidence to support its case. Generic Health, on the other hand, contended that allowing such observation would compromise its intellectual property and commercial interests. The Court had to balance Bayer's right to inspect against Generic Health's rights to protect its confidential information.
The Court held that Bayer's application for leave to observe the manufacturing process was an attempt to obtain evidence by circumventing the standard discovery process. It found that Bayer had not demonstrated that the evidence sought could not be obtained by other means. The Court also noted the significant burden that such an inspection would place on Generic Health, particularly regarding the protection of its intellectual property. Consequently, the Court dismissed Bayer's application for leave and ordered that Generic Health was to pay Bayer's costs of the interlocutory application.
Orders
Orders of the court
1. The interlocutory application filed 5 March 2013 be dismissed.
2. The respondents are to pay the applicants’ costs of the interlocutory application as agreed or taxed.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.